Evaluating the relationship between human papilloma virus infections, prostate cancer and interleukin-12 levels

Prostate cancer (PC); is the second leading cause of cancer mortality among men. Human papillomavirus (HPV) is the most common cause of cervical cancer, strongly associated with anal and vaginal cancers. Also, interleukin-12 (IL-12) induces antitumor immunity. This study aimed to investigate the role of HPV in PC; and determine its effects on serum IL-12. Between 2018 and 2022 in Ahvaz, researchers obtained 55 paraffin samples of malignant prostate lesions and 55 control samples of benign hyperplasia tissues from the prostate. Blood samples were collected from 24 diagnosed cancer patients to assess IL-12 levels before treatment initiation. Additionally, 24 patients with benign prostatic hyperplasia participated as controls. We performed DNA extraction using the phenol-chloroform method and examined the presence of papillomavirus DNA in tissues through Nested-PCR. Subsequently, IL-12 levels in serum were measured using ELISA. The findings did not show the relationship between HPV and PC; HPV infection was not correlated to the presence of IL-12 secretion. However, with the progression of cancer, the level of IL-12 decreased significantly in patients compared to the control group (p < 0.05). HPV infection can exist in prostate tissue, although this does not mean that it contributes to P.C. development. The most significant strains infecting prostate tissue are types 16 and 18. Compared to the control group and with different Gleason scores, prostate cancer patient’s levels of IL-12 secretion are significantly lower. One can make effective measures to assess the prognosis, regulate the condition, or aid in treating individuals using this crucial cytokine.

1. Amadi, V., Nwiabu N., Anireh V. Case-based reasoning system for the diagnosis and treatment of breast, cervical and prostate cancer. SSRG IJCSE, 2021, Vol. 8, no. 8, pp. 13-20.

2. Atashafrooz F., Rokhbakhsh-Zamin F. Frequency and type distribution of human papilloma virus in patients with prostate cancer, Kerman, Southeast of Iran. Asian Pac. J. Cancer Prev., 2022, 174, pp. 57-67.

3. Bae J.M. Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive metaanalysis. Epidemiol. Health, 2015, Vol. 37, e2015005. doi: 10.4178/epih/e2015005.

4. Bagcchi S. Harald zur Hausen. Lancet Infect. Dis., Vol. 23, no. 9, 1001. doi: 10.1016/S1473-3099(23)00511-X.

5. Bermúdez-Morales V.H., Fierros-Zarate G., García-Meléndrez C., Alcocer-Gonzalez J.M., MoralesOrtega A., Peralta-Zaragoza O., Torres-Poveda k., Burguete-García AI., Hernández-Márquez E., Madrid-Marina V. In vivo Antitumor Effect of an HPV-specific Promoter driving IL-12 Expression in an HPV 16-positive Murine Model of Cervical Cancer. J. Cancer, 2016, Vol. 7, no. 14, pp. 1950-1959.

6. Bermúdez-Morales V.H., Peralta-Zaragoza O., Alcocer-González J.M., Moreno J., Madrid-Marina V. IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol. Med. Rep., 2011, Vol. 4, no. 2, pp. 369-375.

7. Berraondo P., Prieto J., Aseguinolaza G.G. Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther., 2009, Vol. 9, no. 2, pp. 62-71.

8. Chen A.C.-H., Waterboer T., Keleher A., Morrison B., Jindal S., McMillan D., Nicol D., Gardiner R.A., McMillan N.A.J., Antonsson A. Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients. Pathol. Oncol. Res., 2011, Vol. 17, no. 3, pp. 613-617.

9. Croxford A.L., Kulig P., Beche B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev., 2014, Vol. 25, no. 4, pp. 415-421.

10. Feng Q., Wei H., Morihara J., Stern J., Yu M., Kiviat N., Hellstrom I., Hellstrom K.E. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol. Oncol., 2012, Vol. 127, no. 2, pp. 412-419.

11. Guenova E., Volz T., Sauer K., Kaesler S., Müller M.R., Wölbing F., Chen K., Schwärzler C., Brossart P., Röcken M., Biedermann T. IL-4-mediated fine tuning of IL-12p70 production by human DC. Eur. J. Immunol., 2008, Vol. 38, no. 11, pp. 3138-3149.

12. Guma S., Maglantay R., Lau R., Wieczorek R., Melamed J., Deng F.M., Zhou M., Makarov D., Lee P., Pincus M.R., Pei Z.H. Papillary urothelial carcinoma with squamous differentiation in association with human papilloma virus: case report and literature review. Am. J. Clin. Exp. Urol., 2022, Vol. 174, pp. 57-67.

13. Habiba U.E., Rafiq M., Khawar M.B., Nazir B., Haider G., Nazir N. The multifaceted role of IL-12 in cancer. Adv. Cancer Biol.-Met., 2022, Vol. 5, 100053. doi: 10.1016/j.adcanc.2022.100053.

14. Jebreel A., Mistry D., Loke D., Dunn G., Hough V., Oliver K., Stafford N., Greenman J. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J. Laryngol. Otol., 2007, Vol. 121, no. 3, pp. 246-252.

15. Khatami A., Sadri Nahand J., Kiani S.J., Khoshmirsafa M., Moghoofei M., Khanaliha K., Tavakoli A., Emtiazi N., Bokharaei-Salim F. Human papilloma virus (HPV) and prostate cancer (PCa): The potential role of HPV gene expression and selected cellular MiRNAs in PCa development. Microb. Pathog., 2022, Vol. 166, 105503. doi: 10.1016/j.micpath.2022.105503.

16. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed. Pharmacother., 2001, Vol. 55, no. 2, pp. 111-116.

17. Kundu M., Roy A., Pahan K. Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-γ. Proc. Natl. Acad. Sci. USA, 2017, Vol. 114, no. 43, pp. 11482-11487.

18. Lawson J.S., Glenn W.K. Evidence for a causal role by human papillomaviruses in prostate cancer – a systematic review. Infect. Agent. Cancer, 2020, Vol. 15, 41. doi: 10.1186/s13027-020-00305-8.

19. Ma W., Wang K., Du J., Luan J., Lou G. Multi-dose parecoxib provides an immunoprotective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer. Mol. Med. Rep., 2015, Vol. 11, no. 4, pp. 2999-3008.

20. Mahmoudia S., Jafari-Salesb A., Nasiric R., Baghi H.B. Prostate cancer and human papillomavirus infection: a recent literature review. Rev. Res. Med. Microbiol., 2022, Vol. 33, pp. 100-108.

21. Mahvi D.M., Henry M.B., Albertini M R., Weber S., Meredith K., Schalch H., Rakhmilevich A., Hank J., Sondel P. Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial. Cancer Gene Ther., 2007, Vol. 14, no. 8, pp. 717-723.

22. Marcuccilli F., Farchi F., Mirandola W., Ciccozzi M., Paba P., Bonanno E., Perno C.F., Ciotti M. Performance evaluation of Anyplex™II HPV28 detection kit in a routine diagnostic setting: comparison with the HPV Sign® Genotyping Test. J. Virol. Methods, 2015, Vol. 217, pp. 8-13.

23. Medel-Flores O., Valenzuela-Rodríguez V.A., Ocadiz-Delgado R., Castro-Muñoz L.J., Hernández-Leyva S., Lara-Hernández G., Silva-Escobedo J.G., Vidal P.G., Sánchez-Monroy V. Association between HPV infection and prostate cancer in a Mexican population. Genet. Mol. Biol., 2018, Vol. 41, no. 4, pp. 781-789.

24. Mesri E.A., Feitelson M.A., Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe, 2014, Vol. 15, no. 3, pp. 266-282.

25. Michopoulou V., Derdas S.P., Symvoulakis E., Mourmouras N., Nomikos A., Delakas D., Sourvinos G., Spandidos D.A. Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients. Tumour Biol., 2014, Vol. 35, no. 12, pp. 12765-12773.

26. Minichsdorfer C. HPV-associated cancers. Memo, 2019, Vol. 12, pp. 352-356.

27. Moghoofei M., Keshavarz M., Ghorbani S., Babaei F., Nahand J.S., Tavakoli A., Mortazavi H.S., Marjani A., Mostafaei S., Monavari S.H. Association between human papillomavirus infection and prostate cancer: A global systematic review and meta-analysis. Asia Pac. J. Clin. Oncol., 2019, Vol. 15, no. 5, pp. e59-e67.

28. Murakami S., Okubo K., Tsuji Y., Sakata H., Hamada S., Hirayama R. Serum interleukin-12 levels in patients with gastric cancer. Surg. Today, 2004, Vol. 34, no. 12, pp. 1014-1019.

29. Nahand J.S., Esghaei M., Monavari S.H., Moghoofei M., Kiani S.J., Mostafaei S., Mirzaei H., BokharaeiSalim F. The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in Prostate cancer. Int. Immunopharmacol., 2020, Vol. 88, 106913. doi: 10.1016/j.intimp.2020.106913.

30. Negin F.A. Immunotherapy of prostate cancer by a combination of treatments aiming at activation of OX40 and intratumoral production of IL-12. Amazon, 2012, Vol. 72, no. 1, pp. 12-23.

31. Okunade K.S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol., 2020, Vol. 40, no. 5, pp. 602-608.

32. Opeyemi Bello R., Willis-Powell L., James O., Sharma A., Marsh E., Ellis L., Gaston K., Siddiqui Y. Does human papillomavirus play a causative role in prostate cancer? A systematic review using Bradford Hill’s сriteria. Cancers, 2023, Vol. 15, no. 15, 3897. doi: 10.3390/cancers15153897.

33. Paz F.G., Marina V.M., Ortega A.M., González A.S., Zaragoza O.P., García A.B., Poveda K.T., Moreno J., González J.A., Marquez E.H., Morales V.B. The Relationship between the antitumor effect of the IL-12 gene therapy and the expression of Th1 cytokines in an HPV16-positive murine tumor model. Mediators Inflamm., 2014, Vol. 2014, 510846. doi: 10.1155/2014/510846.

34. Rosalik K., Tarney C., Han J. Human papilloma virus vaccination. Viruses, 2021, Vol. 13, no. 6, 1091. doi: 10.3390/v13061091.

35. Russo G., Calogero A.E., Condorelli R.A., Scalia G., Morgia G., Vignera S.L. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male, 2020, Vol. 23, no. 2, pp. 132-138.

36. Salimu J., Webber J., Gurney M., Al-Taei S., Clayton A., Tabi Z. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. J. Extracell. Vesicles, 2017, Vol. 6, no. 1, 1368823. doi: 10.1080/20013078.2017.1368823.

37. Shariat A., Arzani P., Shirali M. Studying the association between human papillomavirus and prostate cancer by immunohistochemistry and PCR techniques in ahvaz hospitals. JSMJ, 2020, Vol. 19, no. 4, pp. 425-434.

38. Shekar A.M., Bahar B., Behbin M., Atri M., Falak R., Imani M., Danesh P. The evaluation of serum levels of IFN-γ, IL-12 and percentage of CD4+, CD8+ and NK cells in peripheral blood of metastatic, nonmetastatic breast cancer patients and normal individuals. RJMS, 2008, Vol. 14, no. 57, pp. 113-120.

39. Shi G., Edelblute C, Arpag S., Lundberg C., Heller R. IL-12 gene electrotransfer triggers a change in immune response within mouse tumors. Cancers, 201, Vol. 10, no. 12, 498. doi: 10.3390/cancers10120498.

40. Tolstov Y., Hadaschik B., Pahernik S., Hohenfellner M., Duensing S. Human papillomaviruses in urological malignancies: a critical assessment. Urol. Oncol., 2014, Vol. 32, no. 1, pp. 46.e19-e27.

41. Torres-Poveda K., Bahena-Román M., Madrid-González C., Burguete-García A., Bermúdez-Morales V.H., Peralta-Zaragoza O., Madrid-Marina V. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J. Clin. Oncol., 2014, Vol. 5, no. 4, pp. 753-763.

42. Tugues S., Burkhard S.H., Ohs I., Vrohlings M., Nussbaum K., Vom Berg J., Kulig P., Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ., 2015, Vol. 22, no. 2, pp. 237-246.

43. Usman M., Ahmad M., Hameed Y., Ahmed H., Safdar Hussain M.,Rehman J.U., Arshad R., Atif M. Identification of correlation betweenhuman papillomavirus and prostate cancer:Bradford Hill Criteria Based Evaluation. Int. J. Endorsin, 2021, pp. 248-256.

44. Videla S., Darwich L., Cañadas M., Clotet B., Sirera G. Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages. Expert Rev. Anti Infect. Ther., 2014, Vol. 12, no. 8, pp. 947-957.

45. Yang L., Xie S., Feng X., Chen Y., Zheng T., Dai M., Zhou C.k., Hu Z., Li N., Hanga D. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: A Meta-analysis. Sci. Rep., 2015, Vol. 5, 14667. doi: 10.1038/srep14667.

46. Yin X., Yan X., Yang Q., Cao H., Liang H. Antitumor mechanism of recombinant murine interleukin-12 vaccine. Cancer Biother. Radiopharm., 2010, Vol. 25, no. 3, pp. 263-268.

47. Yu L., Majerciak V., Zheng Z.-M. HPV16 and HPV18 genome structure, expression, and post-transcriptional regulation. Int. J. Mol. Sci., Vol. 23, no. 9. 4943. doi: 10.3390/ijms23094943.